oppn parties Covid Vaccines Cannot Be Priced As Any Other Vaccine

News Snippets

  • Supreme Court sentences Congress leader Navjot Singh Sidhu to one year rigorous imprisonment in the 1988 road rage case
  • Home Minister Amit Shah says rights should not be demanded before fulfilling responsibilities and that universities are no place to wage ideological battles
  • NIA court convicts JKLF chief Yasin Malik in terror funding case after he pleads guilty of all charges
  • A study backed by PM-EAC has recommended universal basic income and urban job guarantee and greater spend on social sector schemes
  • Supreme Court rules that the decisions of the GST Council are not binding on the Centre and the states, leaving the door open for states to levy further taxes
  • After sustained campaign by BJP MP Arjun Singh, the Centre today withdrew the jute price cap order, industry welcomes move
  • Akasa Air might postpone its July launch due to late arrival of aircrafts
  • Metro Cash & Carry decides to sell Indian operations. All major players, including Reliance retail and Amazon, are likely to bid
  • Local and global cues spook the markets on Friday - Sensex crashes 1416 points to 52792 and Nifty by 430 points to 15809
  • IPL: RCB crushes GT by 8 wickets as Virat Kohli returns to form with a well-made half century
  • Nikhat Zareen is world champion in flyweight category. Wins gold at Women's World Championships at Instanbul
  • Supreme Court uses its special powers under Article 124 to release A G Perarivalan, a Rajiv Gandhi assassination convict
  • Indrani Mukherjea, prime accused in the Sheena Bora murder case, gets bail from Supreme Court after 6.5 years in jail
  • Hardik Patel quits Congress, says top leaders distracted by mobile phones and state leadership busy arranging 'chicken sandwiches' for them
  • Anil Baijal resigns as Lieutenant Governor of Delhi citing "personal reasons"
Nikhat Zareen is crowned world champion in the flyweight (52Kg) category at the Women's World Championships in Istanbul /////// Supreme Court sentences Navjot Singh Sidhu to rigorous imprisonment of one year in the road rage case /////// Sunil Jakhar, who quit the Congress a few days ago, joins the BJP
oppn parties
Covid Vaccines Cannot Be Priced As Any Other Vaccine

By Sunil Garodia
First publised on 2021-06-16 11:38:25

About the Author

Sunil Garodia Editor-in-Chief of indiacommentary.com. Current Affairs analyst and political commentator.

Both Serum Institute and Bharat Biotech, makers of Covishield and Covaxin respectively, have urged the government to raise the price at which it is acquiring the Covid vaccines from them. Their argument is that the average price (reported to be in the range of Rs 200 to Rs 250 per dose excluding taxes) now is not sustainable due to the fact that a lot of costly R&D went into developing the vaccines and they have to upgrade their facilities. They say that at current price, they are just recouping their costs and making a small profit. But, they say, they have to make super profits to recoup R&D costs and for future R&D.

Their arguments are perfectly logical. But that is in the case of any other vaccine. In case of Covid vaccines, these arguments do not hold. For, most other vaccines take years to develop and then several more years to test and market. The Covid vaccines were developed, tested and administered in a record 10 to 11 months. Then, most other vaccines are sold in thousands of doses over a period of several years. Here we are talking about millions of doses in a span of just one year. Also, most other vaccines need extensive marketing which is a costly exercise. Commissions have to be paid at each point in the sales channel. Even doctors have to be 'paid' to prescribe their brand if there are competing vaccines. Companies also have attractive schemes for the trade (like "buy three, get two free" etc) for most other vaccines. Lastly, in all other vaccines, there are expired and unsold products, sometimes to the extent of 5% of sales, which the companies have to take back from the market. The companies are saving all these costs. Further, in the case of Covaxin, the government of India, through ICMR, has contributed funds in R&D.

If the companies say that these costs are not sustainable, the government must sit with them to renegotiate the price. But the pricing of vaccines which are to be procured in millions of doses in a short span of time and for which the government is making advance payment in part cannot be priced in a manner similar to any other vaccine. The companies have to keep this in mind.